免疫治疗新进展讲义.pptVIP

主要终点PFS、次要终点ORR NIVO + IPI (N = 314) NIVO (N = 316) IPI (N = 315) Median PFS,months (95% CI) 11.5 (8.9–16.7) 6.9 (4.3–9.5) 2.9 (2.8–3.4) HR (95% CI)vs IPI 0.42 (0.31–0.57)* 0.57 (0.43–0.76)* -- HR (95% CI)vs NIVO 0.74 (0.60–0.92)** -- -- ORR (95% CI) 57.6% (52.0–63.2)* 43.7% (38.1–49.3)* 19.0% (14.9–23.8) CR rate 11.5% 8.9% 2.2% * Jedd D. Wolchok, et al. 2015 ASCO Annual Meeting abstr LBA1. *P 0.00001 vs IPI. **Study not statistically powered for this comparison. 研究结论 NIVO + IPI 及 NIVO 单药 临床疗效优于 IPI 单药 NIVO + IPI 与 NIVO 单药结果对比提示二者具有疗效互补作用 NIVO + IPI 未观察到新的安全事件或药物相关性死亡 Jedd D. Wolchok, et